TORONTO , March 2, 2017 /CNW/ - ProMIS Neurosciences ("ProMIS" or the "Company"), a company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the appointment of Anthony J. Giovinazzo , MBA, to its Board of Directors, effective immediately.
"I first met Anthony over twenty years ago, working together on an Alzheimer's diagnostics opportunity" stated Eugene Williams , ProMIS Executive Chairman. "He and I have been talking about a shared commitment to making a difference in Alzheimer's for a long time. After the outstanding job that Anthony did at Cynapsus, for both Parkinson's patients and shareholders, he has many alternatives. We are thrilled that he has chosen to apply his talents and energy to ProMIS".
Anthony Giovinazzo is currently President and CEO of Sunovion CNS Development Canada ULC. As President and CEO of Cynapsus Therapeutics from 2009 through 2016 he led the successful purchase of Cynapsus by Sunovion Pharmaceuticals, a member of the Dainipon Sumitomo Pharma group of Japan . At Cynapsus, Anthony led the successful development of APL 130277 (a sublingual strip of apomorphine) through to late stage Phase 3 studies and was responsible for Cynapsus up-listing from the TSX Venture exchange to the TSX and then the NASDAQ.
"I am delighted to join the Board of Directors of ProMIS Neurosciences," stated Mr. Giovinazzo. "Having devoted most of my career to the development and commercialization of therapies for neurodegenerative disease, I look forward to leveraging my experience to support the Company as it develops innovative, precision medicine therapeutics for Alzheimer's disease and ALS".
About Anthony Giovinazzo , MBA.
Anthony J. Giovinazzo has over thirty-eight years of professional experience. His first seven years were spent as an international corporate tax specialist primarily in multinational conglomerates. Over the subsequent eight years Anthony worked in Fortune 100 investment banking and private equity. For the last twenty-three years he worked exclusively on the discovery, development and commercialization of neurodegenerative disease therapeutics. His primary areas of focus have been Alzheimer's, Parkinson's and neuropathic pain.
Since October 2016 he has been the President and CEO of Sunovion CNS Development Canada ULC., a successor company to Cynapsus Therapeutics Inc., which was purchased by Sunovion Pharmaceuticals Inc., a member of the Dainipon Sumitomo Pharma group of companies of Japan . He was President, CEO and a Director of Cynapsus Therapeutics Inc. from 2009 to 2016 and was one of the three original inventors and patent holders of the Cynapsus Parkinson's focussed technology. Under his leadership the company successfully developed APL 130277 (a sublingual strip of apomorphine for OFF episodes) through to late stage Phase 3 studies. In addition, Anthony led the up-listing of Cynapsus from the TSX Venture exchange to the TSX and then the NASDAQ, attracting bulge bracket investment banks and some of the largest institutional life science investors in the USA . The sale of Cynapsus to Sunovion in 2016 resulted in a 120% premium to market price ( CDN$841 million ) via an all cash M&A transaction.